Founded in 2015, Lunghealth Medtech specializes in the development of early precision diagnosis and treatment of lung cancer. The company develops a new generation of minimally invasive interventional technologies such as flexible endoscopic surgical robots through natural orifices and over-the-horizon precise lung navigation.
Shanghai Lunghealth Medtech (Chinese: 朗合医疗) recently announced the completion of a CNY 100 million (USD 16 million) series B funding round.
This round was led by Yinglian Health Fund, with follow-on participation from existing shareholders Qianhou Yingkang Fund, Sharelink Capital and Taikun Fund.
The proceeds will be utilized to expand the company's competitive edge in natural orifice surgical robots and minimally invasive pulmonary interventional precision diagnosis and treatment and to accelerate the clinical trial and commercialization of its product portfolios.
Lunghealth Medtech has deployed new-generation tumor minimally invasive interventional technologies such as flexible endoscopic surgical robots through natural orifices and over-the-horizon precise lung navigation.
The start-up has successfully landed EU CE qualification and Chinese Quality System certification. With an R&D headquarters in Shanghai and a 5,000-square-meter GMP production base, Lunghealth strives to provide subversive platform-based minimally invasive diagnosis and treatment solutions for various diseases including lung cancer.
Lung cancer is one of the most prevalent cancers in China while patients are troubled by complicated biopsy processes and severe traumas.
According to Yinglian Health Fund, "surgical robots will provide more accurate solutions to the current dilemma. Lunghealth’s surgical robot R&D progress is at the forefront of the industry in the country, and the product portfolio of respiratory intervention is extensive. A comprehensive solution to the lung cancer for healthcare providers and patients will emerge once the products are launched sequentially,”
"Lunghealth Medtech will continue to explore an innovative path to achieve multi-indication coverage and multi-technology integration. We expect to create a new generation of surgical solutions through natural orifices,” said Dr. Ma Jiajun, founder and CEO of Lunghealth Medtech.
Lunghealth Medtech’s main competitors include Micro-Tech Group (Chinese: 南微医学, SHA:688029), Eco Medtech (Chinese:亿高), Accu Target (Chinese:导向医疗).